Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

eClinicalMedicine（2023）

引用 0|浏览25

暂无评分

摘要

Jiangsu Hengrui Pharmaceutical Co., Ltd.

查看译文

关键词

Camrelizumab, Famitinib, Nasopharyngeal carcinoma, PD-1 inhibitor, Retreatment, VEGFR

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要